v3.22.1
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue $ 0 $ 0
Expenses:    
Research and development 7,393 8,228
General and administrative 4,107 8,024
Operating expenses 11,500 16,252
Other income (expense):    
Interest income 22 27
Foreign exchange loss (3) (2)
Total other income 19 25
Net loss and comprehensive loss $ (11,481) $ (16,227)
Basic and diluted loss per common share (in dollars per share) $ (0.12) $ (0.18)
Weighted average number of common shares outstanding used in the calculation of (in thousands)    
Basic and diluted loss per common share (in shares) 92,226 88,884

Source